Physician profile

Joseph Chiaramonte

Internal Medicine · Tampa, FL

NPI 1982609947

$5,084.21

in general payments reported to CMS, 2019-2025

34 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $698.63 2019-2020
Novo Nordisk INC $588.58 2019-2020
Astrazeneca Pharmaceuticals LP $576.98 2019-2020
Amgen INC. $320.48 2019-2020
Antares Pharma, INC. $311.05 2019-2020
Amarin Pharma, INC. $297.62 2019-2020
Janssen Pharmaceuticals, INC $272.21 2019-2020
Teva Pharmaceuticals USA, INC. $202.83 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $180.06 2019-2020
Glaxosmithkline, LLC. $179.28 2019-2020
Lilly USA, LLC $169.39 2019-2020
Aytu Biopharma, INC. $146.52 2019-2020
Merck Sharp & Dohme LLC $129.09 2019-2020
Avanir Pharmaceuticals, INC. $124.96 2019
Pfizer INC. $99.40 2019-2020
Show all 34 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Joseph Chiaramonte

$5,084.21

in general payments reported 2019-2025

Years
2019-2020
Top company
Abbvie INC.

https://glasscript.com/doctor/225053/joseph-chiaramonte

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.